Immunome Insider Filing Shows 242k Option Grant to CMO

Rhea-AI Filing Summary

Immunome Inc. (IMNM) filed a Form 4 for Chief Medical Officer Dr. Robert Lechleider, reporting the grant of 242,000 employee stock options on 07/29/2025. The options carry a $10.60 exercise price and expire on 07/28/2035. Vesting terms: 25 % on 07/29/2026, then monthly vesting of the remaining 75 % over 36 months, leading to full vesting by 07/29/2029. After the award, the CMO beneficially owns 242,000 derivative securities; no common-stock holdings or open-market trades were disclosed. The transaction is coded “A” (grant) and is held directly; no 10b5-1 plan was indicated. The filing represents standard incentive compensation with no immediate share dilution or cash impact for investors.

Positive

• 242,000 options granted at market price aligns C-suite incentives with shareholder value appreciation

Negative

• None.

Insights

Compensation Analyst

TL;DR: 242k options granted to CMO at $10.60; standard four-year vesting aligns management with shareholders, negligible near-term dilution.

The award size is meaningful for a mid-cap biotech but falls within typical executive compensation ranges. Setting the strike at market price creates performance alignment: value is only realized if shares appreciate beyond $10.60. Four-year vesting helps retain key scientific leadership through pivotal development milestones. Because no shares were issued today, dilution occurs only upon future exercise, and even then represents roughly 0.8-1 % of current shares outstanding—immaterial in the near term. Overall impact on valuation or cash flow is neutral.

Portfolio Manager

TL;DR: Routine insider option grant; signals commitment but lacks material effect on fundamentals—monitor future exercises.

This Form 4 does not indicate insider buying or selling, merely the granting of options. Such grants are common after senior hires or performance reviews. Investors should note the long-dated expiration (2035), which can become dilutive over time, yet the percentage versus float is modest. No red flags emerge, and the absence of a 10b5-1 reference suggests flexibility in future trading windows. I classify the filing as not impactful to the current investment thesis but useful for tracking insider incentive structures.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lechleider Robert

(Last) (First) (Middle)

C/O IMMUNOME, INC.

18702 N. CREEK PARKWAY, SUITE 100

(Street)

BOTHELL WA 98011

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$10.6	07/29/2025		A		242,000		(1)	07/28/2035	Common Stock	242,000	$0	242,000	D

Explanation of Responses:

1. 25% of the shares subject to the options vest on July 29, 2026, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.

	/s/ Sandra Stoneman, Attorney-in-Fact	07/31/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many stock options were granted to IMNM's CMO?

The Form 4 reports a grant of 242,000 employee stock options.

What is the exercise price of the Immunome (IMNM) options?

Each option carries an exercise price of $10.60 per share.

When do the IMNM options vest?

25 % vest on 07/29/2026; the remaining 75 % vest monthly over the following 36 months, fully vesting by 07/29/2029.

What is the expiration date of the granted options?

The options expire on 07/28/2035.

Did the CMO buy or sell any Immunome common stock?

No common-stock purchases or sales were reported; only an option grant was disclosed.